Processa Pharmaceuticals Overview
Valuation check: PCSA's ROE is 4234.62%, above the Industrials sector average of 8.49%.
Get informed when a big investor buys or sells
+ Follow4234.62%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for PCSA is 4234.62%. That is above the Industrials sector average of 8.49%. Investors often review this figure alongside Processa Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Industrials companies, PCSA currently prints 4234.62% for ROE, while the sector average sits near 8.49%. That is roughly 49797.1% above the sector mean. Large gaps often invite a closer look at Processa Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Processa Pharmaceuticals converts resources into returns. At 4234.62%, PCSA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PCSA's ROE (4234.62%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Processa Pharmaceuticals's ROE against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.
